Blood in the urine as a sign of cancer

.
.

Malignant neoplasms of the kidneys develop mainly in patients older than 50 years. The tumor can reach considerable dimensions, penetrating into the renal capsule and the inferior vena cava. A characteristic feature of the disease is the presence of metastases in regional lymph nodes, lungs and liver. The first symptom of such oncoforming is theblood in the urine, which periodically disappears and appears again.

Blood in the urine as the main sign of kidney cancer

This symptom is called hematuria. It is defined in about 70% of cancer patients. Blood, as a rule, appears against the background of a safe overall health. In some cases, hemorrhagic signs are preceded by moderate renal pain. After this, the patient can observe a traditional attack of colic, which disappears after the release of the last clot of blood. Periodic blood in the urine with cancer leads to the development of anemia (insufficient blood in the circulatory system).

Other signs of cancer of kidney tissues include:

  • Prolonged fever, in which temperature values ​​can fluctuate within 37 ° -3, ° C.
  • Paroxysmal pain in the affected kidney. Pain syndrome, as the size of the neoplasm increases, becomes more intense and sharper.
  • Swelling of the kidney tissues, which can be determined by probing.
  • Cancer intoxication of the body: general malaise, weakness, nausea and loss of appetite.
.
.

Analyzes and examinations to be completed

Clinical examination of the kidneys for the detection of malignant neoplasm, as a rule, begins after detection in the patient of a hematuria, painful attacks in the field of a loin and chronic subfebrile temperature. A specialized examination of the patient includes the following diagnostic procedures:

  1. Excretory urography - this radiographic examination of the urinary tract is based on a series of X-ray images showing the excretion of contrast substance. Radiopaque preparation, consisting of a concentrated solution of iodine, is administered intravenously. This examination determines the state of the kidney and urinary tract.
  2. The analysis of blood and urine on tumor markers, which allows to suspect the development of the tumor and monitor the effectiveness of anti-cancer treatment.
  3. Ultrasound examination - determines the outlines and localization of malignant neoplasm.
  4. Computer and magnetic resonance imaging - in more detail show the structure of the kidney tissues.
  5. Biopsy - cytological and histological analysis of the pathological focus sets the final diagnosis.

Treatment

The most optimal way of treating this pathology is a surgical operation aimed at complete removal of the cancer tumor together with the organ. The implementation of radical excision is advisable at all stages of malignant growth. This allows the patient to get rid of blood in the urine and pain syndrome. The only contraindication for surgical intervention is the unsatisfactory general condition of the oncological patient.

In addition to the basic treatment, doctors can prescribe chemotherapy. Approximately 40% of patients after the course of taking cytotoxic drugs noted the stabilization of cancer progress. Duration of admission and dosage of a chemotherapeutic agent are determined individually for each patient.

And yet, in most clinical cases, therapy of this pathology is palliative, which consists in the temporary elimination of pain and discomfort. Symptomatic treatment is associated with the presence of multiple metastases in the lungs, the liver and the central nervous system.

Prognosis and average survival of patients with oncological hematuria

Longevity of cancer patients largely depends on the stage of the disease, which was the primary diagnosis. The most favorable prognosis in patients at the initial phase of malignant growth. But sinceblood in the urine, as a sign of cancer indicates a more advanced stage of oncology, then the outlook becomes negative. So, according to statistics, the average survival rate of patients with kidney cancer after a radical intervention does not exceed two years. In these cases, the patient's lifespan depends directly on the number of metastases and the state of his health.

.
.
.
.